Treatment of hypertension from the perspective of an outpatient physician
Authors:
T. Švarcová
Authors‘ workplace:
I. interní kardioangiologická klinika LF UK a FN Hradec KrálovéKardiologická a interní ambulance, Edumed s. r. o., Jaroměř
Published in:
Kardiol Rev Int Med 2016, 18(2): 94-96
Overview
Treatment of hypertension in an outpatient department requires a physician who knows the effects and particularly additional benefits of individual antihypertensive drugs and is able to simplify the treatment and motivate the patient to comply with it. The article discusses the most frequently used groups of antihypertensive drugs and possibilities of simplification of the treatment.
Keywords:
perindopril – amlodipine – thiazides – thiazide-like diuretics – combination-dose therapy
Sources
1. Studie post‑MONICA potvrzuje pozitivní trendy. Medical Tribune 2015; 26. Dostupné z: http:/ / www.tribune.cz/ clanek/ 38057-studie-post-monica-potvrzuje-pozitivni-trendy.
2. Václavík J. Obtížně léčitelná hypertenze. Praha: Mladá Fronta 2015: 15– 19.
3. Poulter NR. Multiple combination therapy in hypertension. Oxford: Nova Professional Media Limited 2014: 18– 19.
4. Wald DS, Law M, Morris JK et al. Combination therapy vs. monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009; 122: 290– 300. doi: 10.1016/ j.amjmed.2008.09.038.
5. Widimský J. Hypertenze. Praha: Triton 2008: 334– 357.
6. van Vark LC, Bertrand M, Akkerhuis KM et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin- angiotensin- aldosterone system inhibitors involving 158 998 patients. Eur Heart J 2012; 33: 2088– 2097. doi: 10.1093/ eurheartj/ ehs075.
7. Savarese G, Costanzo P, Cleland J et al. A Meta-analysis reporting effects of angiotensin – converting enzyme inhibitors and angiotensin receptor blockers in patients without heart failure. J Am Coll Cardiology 2013; 61: 131– 142. doi: 10.1016/ j.jacc.2012.10.011.
8. DiNicolantonio JJ, Lavie CJ, O’Keefe JH et al. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med 2013; 125: 154– 168. doi: 10.3810/ pgm.2013.07.2687.
9. Pitt B, Byington RP, Furberg CD et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503– 1510.
10. Morgan T. Twenty four hour BP kontrol – which is best, trough: peak ratios or ABPM? Brit J Cardiol 1995; (Suppl 1): S7–S9.
11. Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417– 2428. doi: 10.1056/ NEJMoa0806182.
12. Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trila. Lancet 2005; 366: 895– 906.
13. Rosolová H. Diuretika v léčbě arteriální hypertenze. Acta Medicinae 2015; 8: 35– 36.
14. Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57: 590– 600. doi: 10.1016/ j.jacc.2010.07.053.
15. Olde Engberink RH, Frenkel WJ, van den Bogaard B et al. Effects of thiazide-type and thiazide- like diuretics on cardiovascular events and mortality. Hypertension 2015; 65: 1033– 1040. doi: 10.1161/ HYPERTENSIONAHA.114.05122.
16. Holaj R. Kombinační léčba hypertenze. Causa Subita 2015; 4: 138– 143.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
![Issue 2](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/112c4e8e48f4e6608ac78fdc9ecb823d.jpeg)
2016 Issue 2
Most read in this issue
- Fixed-dose combinations in dyslipidemy treatment
- Sacubitril-valsartan (LCZ696) in the treatment of heart failure
- Fixed-dose combination therapy for hypertension
- Fixed-dose combination in pulmonology